Pharma BD Deal Intelligence
A $280M cash deal for Xcel's neurology portfolio that mostly stalled: retigabine, the marquee pipeline bet, won FDA approval as Potiga in 2011 but was pulled worldwide in 2017 after serious safety warnings, while the four legacy CNS products became durable but minor, undisclosed-revenue tail assets.
Legacy neurology products became durable but minor tail assets; the deal's marquee pipeline bet (retigabine/Potiga) reached FDA approval in 2011 but was commercially withdrawn worldwide in 2017 after serious safety warnings.
Full analysis, sources & comparables →Valeant Pharmaceuticals agreed to acquire San Diego-based Xcel for $280 million in cash plus assumption of $44 million in debt, in a deal aimed at boosting its…
CEO Timothy Tyson said "The Xcel acquisition provides Valeant with access to an excellent market product portfolio and a pipeline product with significant…
GSK paid Valeant $125 million upfront plus up to $545 million in milestone payments for retigabine, "a first in class neuronal potassium channel opener for…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Valeant acquires Xcel Pharmaceuticals in 2005; brought neurology assets including rights to retigabine/ezogabine.
Legacy neurology products became durable but minor tail assets; the deal's marquee pipeline bet (retigabine/Potiga) reached FDA approval in 2011 but was commercially withdrawn worldwide in 2017 after serious safety warnings.
Assessment window: 15yr post-close.
Epilepsy is a chronic neurological disorder characterized by recurrent unprovoked seizures arising from abnormal cortical electrical activity. It affects all ages, with peak incidence at the extremes of life, and roughly one-third of patients fail to achieve seizure freedom on existing antiepileptic drugs (AEDs), creating sustained demand for novel mechanisms.
In 2005 the branded epilepsy market was led by Pfizer's Lyrica (pregabalin) and Neurontin (gabapentin), Johnson & Johnson's Topamax (topiramate), GSK's Lamictal (lamotrigine) and Keppra (levetiracetam) from UCB, with Diastat (rectal diazepam) and Mysoline (primidone) serving niche segments Xcel commercialized. Xcel's pipeline crown jewel was retigabine, a first-in-class neuronal Kv7 potassium-channel opener acquired from Viatris GmbH in 2004, positioned for refractory partial-onset seizures where ~30% of patients remain uncontrolled. The deal added 94 neurology reps, doubling Valeant's specialty footprint to ~200 to support Diastat, Migranal and a planned Zelapar launch. Ultimately Valeant out-licensed retigabine to GSK in August 2008 for $125M upfront plus up to $545M in milestones, and the FDA approved it as Potiga (ezogabine) in 2011; pigmentary side effects led GSK to discontinue Potiga in 2017, while Diastat and Mysoline remained durable cash generators that flowed into Valeant/Bausch Health well past 2015.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Valeant Pharmaceuticals International, Inc. / Xcel Pharmaceuticals, Inc. (this deal) | 2005 | $280M | 42 |
| Valeant Pharmaceuticals International, Inc. / Dow Pharmaceutical Sciences, Inc. | 2009 | $285M | 66 |
| Valeant Pharmaceuticals International, Inc. / iNova Pharmaceuticals | 2011 | $700M | 63 |
| Valeant Pharmaceuticals International, Inc. / Dermik Laboratories (Sanofi dermatology unit) | 2011 | $425M | 36 |
| Valeant Pharmaceuticals International, Inc. / Bausch + Lomb | 2013 | $8.7B | 36 |
| Valeant Pharmaceuticals International, Inc. / Medicis Pharmaceutical Corporation | 2012 | $2.6B | 33 |
| Valeant Pharmaceuticals International, Inc. / PreCision Dermatology, Inc. | 2014 | $475M | 23 |
← Browse all deals · How we score deals
More: 2005 deals · Valeant Pharmaceuticals International, Inc. deals · Neurology deals